0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis

Richard L. Greenman, MD; Roland M. H. Schein, MD; Michael A. Martin, MD; Richard P. Wenzel, MSc, MD; Neil R. Maclntyre, MD; George Emmanuel, MD; Herman Chmel, MD; Richard B. Kohler, MD; Mary McCarthy, MD; Joseph Plouffe, MD; Jane A. Russell, RN; Elena Hollender, MD; Richard Immerman, MD; Michael Pfaller, MD; Carol Sheetz, RN; Peter Jebson, MD; Alison Houston, MT, ASCP; Dawn Rehak, RN; Patricia Empson, RN; Jill Ireland, RRT; Shakti Narain, MD; Jack E. Rashkin, MD; Richard A. Jacobs, MD; Jacqueline Octavio, RN; Rebecca Coleman, PharmD; Vicki S. Kenyon, RN; Bienvenido G. Yangco, MD; John F. Toney, MD; John Edwards, MD; Mark Crislip, MD; Ronald W. Quenzer, MD; Gordon M. Trenholme, MD; Barbara A. Schmitt, RN; Jeffrey E. Grossman, MD; Charles L. Daley, MD; Henry F. Chambers, MD; Paul B. Iannini, MD; Thomas Graziano, MD; Ronald Dandurand, MD; Gary Schieiter, MD; Mark Kunkel, MD; George A. Pankey, MD; Brenda Mayeur, RN; Sandra Abadie-Kemmerly, MD; James Zachery, MD; Michael Meadors, MD; Jeffrey Coco, MD; Charles V. Sanders, MD; W. Lance George, MD; Steven Gardner, MD; Sydney Finegold, MD; Gordon R. Bernard, MD; Paul Bogden, MD; Erlaine Bello, MD; A. Gray Ellrodt, MD; Jan Dauer, MD; Mary S. Riedinger, RN; Burt R. Meyers, MD; Thomas Iberti, MD; J. Peter Rissing, MD; Donald Nelson, MD; Quyen Luu, MD; G. Douglas Campbell, MD; Keith Olsen, PharmD; Alex Carvalho, MD; Arthur E. Brown, MD; Heinz J. Schmitt, MD; Sheldon Brown, MD; Jerome J. Schentag, PharmD; Philip B. Wels, MD; Patricia E. Wing, RN; Lynda S. Welage, PharmD; Richard Quintiliani, MD; P. H. Chandrasekar, MD; Kenneth R. Ratzan, MD; David L. Dunn, MD, PhD; Kenneth Gorelick, MD; Nancy Wedel, MD; Samuel Saks, MD; John Hannigan, MS; Samuel K. Ackerman, MD; Patrick J. Scannon, MD, PhD; David Salsburg, PhD; C. Douglas Webb, PhD
JAMA. 1991;266(8):1097-1102. doi:10.1001/jama.1991.03470080067031.
Text Size: A A A
Published online

Objective.  —To assess the efficacy of adjunctive monoclonal antibody antiendotoxin immunotherapy in patients with gram-negative sepsis.

Design.  —Double-blind, randomized, placebo-controlled trial.

Setting.  —Thirty-three university-affiliated centers, including Veterans Affairs, community, and municipal hospitals.

Patients.  —Hospitalized adults with signs of gram-negative infection and a systemic septic response.

Intervention.  —Patients were assigned to receive either 2 mg/kg of a murine monoclonal antibody directed against gram-negative endotoxin (E5) or placebo. A second infusion was administered 24 hours later.

Main Outcome Measures.  —Mortality over the 30-day study period, resolution of organ failures, and safety.

Results.  —Four hundred eighty-six patients were enrolled. Three hundred sixteen had confirmed gram-negative sepsis (54% bacteremic, 46% nonbacteremic). The survival difference was not statistically significant for all patients. Among patients with gram-negative sepsis who were not in shock at study entry (n = 137), E5 treatment resulted in significantly greater survival (relative risk, 2.3; P =.01). Resolution of individual organ failures was more frequent among these patients, occurring in 19 (54%) of 35 patients in the E5 group vs eight (30%) of 27 in the placebo group (P =.05). Four reversible allergic reactions occurred among 247 patients (1.6%) receiving E5. No other toxicity was identified.

Conclusions.  —Treatment with E5 antiendotoxin antibody appears safe. It reduces mortality and enhances the resolution of organ failure among patients with gram-negative sepsis who are not in shock when treated.(JAMA. 1991;266:1097-1102)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();